* India reports 152,879 new infections
* Deaths rise by 839 to total of 169,275
(Updates with details of Remdesivir ban and federal letter)
By Devjyot Ghoshal and Krishna N. Das
NEW DELHI, April 11 (Reuters) - India on Sunday banned the
export of anti-viral drug Remdesivir and its active
pharmaceutical ingredients as demand rocketed due to a record
surge in COVID-19 infections and led to crippling shortages in
many parts.
New COVID-19 cases surged to 152,879 on Sunday, the sixth
record rise in seven days, overwhelming hospitals in some
regions. India, known as the pharmacy of the world, has already
stalled major exports of coronavirus vaccines.
In addition to the Remdesivir ban "till the situation
improves", the health ministry said in a statement that
manufacturers had been asked to step up supplies.
Seven Indian companies have licensed the drug from Gilead
Sciences GILD.O , with an installed capacity of about 3.9
million units per month, for local use and exports to more than
100 countries.
The companies are: Cipla Ltd CIPL.NS , Dr. Reddy's
Laboratories Ltd REDY.NS , Hetero Labs Ltd, Jubilant Life
Sciences Ltd JULS.NS , Biocon Ltd's BION.NS Syngene, Zydus
Cadila Healthcare Ltd CADI.NS and the Indian unit of Mylan
MYL.O .
The World Health Organization in November issued a
conditional recommendation against the use of Remdesivir in
hospitalised patients, regardless of disease severity, saying
there was no evidence that the drug improved survival and other
outcomes in these patients.
Many countries, including India, however, have continued to
use it.
India leads the world in the daily average number of new
infections reported in more than two weeks, accounting for one
in every six infections reported globally each day, according to
a Reuters tally.
Deaths have also surged, with the health ministry reporting
839 fatalities on Sunday - the highest in over five months -
taking the total to 169,275.
India's tally of more than 13.35 million cases is the
third-highest globally, behind only the United States and
Brazil.
BLACK MARKETING
India's drug regulator and some state governments have in
recent days raised concerns over hoarding and black marketing of
Remdesivir, which in some instances is being sold at over 10
times the maximum retail price.
Social media posts on Sunday showed large queues of people
in the western state of Gujarat waiting to buy Remdesivir
injections for COVID-19 patients.
"Every day the central government is providing 50,000
Remdesivir injections but all of them are getting consumed,"
Rajesh Tope, health minister of India's hardest-hit Maharashtra
state, told reporters this week. "Pharmacists and stockists
might be doing black marketing and that needs to be checked."
The federal health ministry wrote to Maharashtra, which is
home to the financial capital Mumbai, asking local authorities
to improve COVID-19 testing and deploy more manpower.
"Rostering of health care workers, hiring of contractual
health workers need to be expedited," the letter from India's
top health bureaucrat said, flagging an acute shortage of
healthcare workers in seven districts of Maharashtra.
Authorities have blamed the resurgence of the virus mainly
on crowding and a reluctance to wear masks, even as election
rallies and religious gatherings have continued in recent weeks.
Thousands of people thronged the banks of the holy Ganges
River in Haridwar city on Sunday for prayers during the Kumbh
Mela - where up to five million are expected on certain days.
Authorities have made it mandatory for all people entering
the area to take COVID-19 tests. But many devotees on Sunday
gathered by the river without masks, in densely-packed crowds.
(Reporting by Devjyot Ghoshal and Krishna N. Das in New Delhi,
Editing by William Maclean)